Nurses should understand the role and purpose of the new generation of therapies available for patients with cancer. One such drug is the poly (ADP-ribose) polymerase inhibitor olaparib (Lynparza™▼). As it becomes available, it will be important for nurses to understand how it works, how to anticipate any side effects and how to manage these effectively. This article describes the importance of BRCA gene mutations in women with ovarian cancer and introduces olaparib, a targeted agent for use in these women in accordance with its label indication.
Cancer Nursing Practice. 14, 5, 29-36. doi: 10.7748/cnp.14.5.29.e1148
Correspondence Peer reviewThis article has been subject to double-blind review and checked using antiplagiarism software. For related articles visit our online archive and search using the keywords
Conflict of interestArray
Received: 03 October 2014
Accepted: 02 December 2014
or
Alternatively, you can purchase access to this article for the next seven days. Buy now
Are you a student? Our student subscription has content especially for you.
Find out more
